SG Americas Securities LLC Acquires Shares of 77,524 Dynavax Technologies Co. (NASDAQ:DVAX)

SG Americas Securities LLC bought a new stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 77,524 shares of the biopharmaceutical company's stock, valued at approximately $990,000. SG Americas Securities LLC owned about 0.06% of Dynavax Technologies at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. GAMMA Investing LLC grew its position in Dynavax Technologies by 175.5% in the 3rd quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 1,685 shares during the last quarter. US Bancorp DE raised its position in shares of Dynavax Technologies by 291.4% during the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 2,034 shares during the last quarter. Capital Performance Advisors LLP acquired a new position in Dynavax Technologies in the third quarter valued at approximately $45,000. Nisa Investment Advisors LLC increased its holdings in Dynavax Technologies by 44.6% in the third quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company's stock valued at $61,000 after purchasing an additional 1,679 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new position in Dynavax Technologies during the 3rd quarter worth approximately $89,000. 96.96% of the stock is owned by hedge funds and other institutional investors.

Dynavax Technologies Trading Up 0.3 %

Shares of DVAX stock traded up $0.04 during trading hours on Friday, hitting $13.05. 1,109,429 shares of the company were exchanged, compared to its average volume of 1,732,789. The firm has a market cap of $1.72 billion, a P/E ratio of 100.39 and a beta of 1.34. The company has a 50 day simple moving average of $12.78 and a two-hundred day simple moving average of $11.80. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. Dynavax Technologies Co. has a fifty-two week low of $9.74 and a fifty-two week high of $13.89.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported $0.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.10 by $0.02. Dynavax Technologies had a net margin of 7.85% and a return on equity of 3.19%. The firm had revenue of $80.63 million for the quarter, compared to the consensus estimate of $83.64 million. During the same period in the previous year, the firm earned $0.10 EPS. Equities analysts anticipate that Dynavax Technologies Co. will post 0.2 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on DVAX. HC Wainwright increased their target price on Dynavax Technologies from $29.00 to $31.00 and gave the stock a "buy" rating in a report on Tuesday, January 14th. StockNews.com upgraded Dynavax Technologies from a "hold" rating to a "buy" rating in a research note on Tuesday, January 14th.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.